I dont disagree with your analysis other than to say paying a higher premium makes it a lot harder for the acquirer to get the necessary support from their shareholders. Perceptions matter and the acquiring company would need to convince their shareholders and analysts that they havent overpaid and that the deal is a good one. Certainly no matter how much the DCF stands up, there would be shareholders pushing back against a large premium. So in my view, the current share price matters a lot. Selling a 100% premium vs a 600% premium to their shareholders would be vastly different in my view. Of course if the company is private then it doesnt matter as much.
- Forums
- ASX - By Stock
- NEU
- The Whens and Whys of Top Biotech M&A Deals
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.50%
!
$14.07

The Whens and Whys of Top Biotech M&A Deals, page-32
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.07 |
Change
0.070(0.50%) |
Mkt cap ! $1.750B |
Open | High | Low | Value | Volume |
$14.09 | $14.19 | $13.76 | $788.6K | 56.19K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 188 | $14.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.08 | 265 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 183 | 14.060 |
3 | 223 | 14.050 |
5 | 508 | 14.040 |
5 | 1168 | 14.030 |
8 | 1452 | 14.020 |
Price($) | Vol. | No. |
---|---|---|
14.080 | 898 | 7 |
14.090 | 2478 | 6 |
14.100 | 1461 | 9 |
14.110 | 1151 | 5 |
14.120 | 1052 | 4 |
Last trade - 10.59am 03/07/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RAC
RACE ONCOLOGY LTD
Dr Pete Smith, Executive Chairman
Dr Pete Smith
Executive Chairman
Previous Video
Next Video
SPONSORED BY The Market Online